Logo image of GYRE

GYRE THERAPEUTICS INC (GYRE) Stock Fundamental Analysis

NASDAQ:GYRE - Nasdaq - US4037831033 - Common Stock - Currency: USD

8.71  -0.1 (-1.14%)

After market: 8.4363 -0.27 (-3.14%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to GYRE. GYRE was compared to 563 industry peers in the Biotechnology industry. While GYRE has a great health rating, its profitability is only average at the moment. GYRE is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

GYRE had negative earnings in the past year.
GYRE had a negative operating cash flow in the past year.
GYRE had negative earnings in 4 of the past 5 years.
GYRE had negative operating cash flow in 4 of the past 5 years.
GYRE Yearly Net Income VS EBIT VS OCF VS FCFGYRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

GYRE has a better Return On Assets (9.64%) than 95.20% of its industry peers.
GYRE has a better Return On Equity (19.09%) than 96.27% of its industry peers.
With an excellent Return On Invested Capital value of 11.81%, GYRE belongs to the best of the industry, outperforming 96.09% of the companies in the same industry.
Industry RankSector Rank
ROA 9.64%
ROE 19.09%
ROIC 11.81%
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
GYRE Yearly ROA, ROE, ROICGYRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

Looking at the Profit Margin, with a value of 11.43%, GYRE belongs to the top of the industry, outperforming 94.49% of the companies in the same industry.
GYRE has a better Operating Margin (15.35%) than 95.56% of its industry peers.
Looking at the Gross Margin, with a value of 96.33%, GYRE belongs to the top of the industry, outperforming 94.85% of the companies in the same industry.
Industry RankSector Rank
OM 15.35%
PM (TTM) 11.43%
GM 96.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GYRE Yearly Profit, Operating, Gross MarginsGYRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K

More info and screens

7

2. Health

2.1 Basic Checks

GYRE has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
GYRE has more shares outstanding than it did 1 year ago.
GYRE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for GYRE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GYRE Yearly Shares OutstandingGYRE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
GYRE Yearly Total Debt VS Total AssetsGYRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

GYRE has an Altman-Z score of 8.81. This indicates that GYRE is financially healthy and has little risk of bankruptcy at the moment.
GYRE has a better Altman-Z score (8.81) than 87.39% of its industry peers.
GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.81
ROIC/WACC1.17
WACC10.13%
GYRE Yearly LT Debt VS Equity VS FCFGYRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

GYRE has a Current Ratio of 3.32. This indicates that GYRE is financially healthy and has no problem in meeting its short term obligations.
GYRE's Current ratio of 3.32 is on the low side compared to the rest of the industry. GYRE is outperformed by 61.99% of its industry peers.
GYRE has a Quick Ratio of 2.99. This indicates that GYRE is financially healthy and has no problem in meeting its short term obligations.
GYRE has a Quick ratio of 2.99. This is in the lower half of the industry: GYRE underperforms 62.52% of its industry peers.
Industry RankSector Rank
Current Ratio 3.32
Quick Ratio 2.99
GYRE Yearly Current Assets VS Current LiabilitesGYRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

GYRE shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.41%.
Looking at the last year, GYRE shows a decrease in Revenue. The Revenue has decreased by -6.78% in the last year.
Measured over the past years, GYRE shows a very strong growth in Revenue. The Revenue has been growing by 78.95% on average per year.
EPS 1Y (TTM)-1.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.66%
Revenue 1Y (TTM)-6.78%
Revenue growth 3Y802.05%
Revenue growth 5Y78.95%
Sales Q2Q%-75.43%

3.2 Future

Based on estimates for the next years, GYRE will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.29% on average per year.
Based on estimates for the next years, GYRE will show a very strong growth in Revenue. The Revenue will grow by 115.68% on average per year.
EPS Next Y590.45%
EPS Next 2Y7.1%
EPS Next 3Y28.26%
EPS Next 5Y19.29%
Revenue Next Year-84.37%
Revenue Next 2Y-41.42%
Revenue Next 3Y186.88%
Revenue Next 5Y115.68%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
GYRE Yearly Revenue VS EstimatesGYRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M
GYRE Yearly EPS VS EstimatesGYRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -500 -1K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GYRE. In the last year negative earnings were reported.
Also next year GYRE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GYRE Price Earnings VS Forward Price EarningsGYRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, GYRE is valued cheaply inside the industry as 93.07% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 43.59
GYRE Per share dataGYRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

GYRE's earnings are expected to grow with 28.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.1%
EPS Next 3Y28.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GYRE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GYRE THERAPEUTICS INC

NASDAQ:GYRE (5/6/2025, 8:13:46 PM)

After market: 8.4363 -0.27 (-3.14%)

8.71

-0.1 (-1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-17 2025-03-17/amc
Earnings (Next)05-08 2025-05-08
Inst Owners1.96%
Inst Owner Change2.41%
Ins Owners6.18%
Ins Owner Change2.25%
Market Cap816.48M
Analysts82.86
Price Target20.4 (134.21%)
Short Float %17.77%
Short Ratio14.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-80.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-19.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.72
P/FCF N/A
P/OCF N/A
P/B 12.89
P/tB 12.95
EV/EBITDA 43.59
EPS(TTM)-2.87
EYN/A
EPS(NY)-2.45
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS1.13
BVpS0.68
TBVpS0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 9.64%
ROE 19.09%
ROCE 15.33%
ROIC 11.81%
ROICexc 15.79%
ROICexgc 15.85%
OM 15.35%
PM (TTM) 11.43%
GM 96.33%
FCFM N/A
ROA(3y)-33.04%
ROA(5y)-63.26%
ROE(3y)-80.93%
ROE(5y)-106.13%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 201.94%
Cap/Sales 2.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.32
Quick Ratio 2.99
Altman-Z 8.81
F-Score5
WACC10.13%
ROIC/WACC1.17
Cap/Depr(3y)333.79%
Cap/Depr(5y)313.61%
Cap/Sales(3y)3.51%
Cap/Sales(5y)4.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.66%
EPS Next Y590.45%
EPS Next 2Y7.1%
EPS Next 3Y28.26%
EPS Next 5Y19.29%
Revenue 1Y (TTM)-6.78%
Revenue growth 3Y802.05%
Revenue growth 5Y78.95%
Sales Q2Q%-75.43%
Revenue Next Year-84.37%
Revenue Next 2Y-41.42%
Revenue Next 3Y186.88%
Revenue Next 5Y115.68%
EBIT growth 1Y-15.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-139.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-114.06%
OCF growth 3YN/A
OCF growth 5YN/A